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ABSTRACT
Objectives. The aim of this study was 
to evaluate the reliability and validity 
of the Turkish translation of the Beliefs 
about Medicines Questionnaire (BMQ-
T, ©Prof. Rob Horne) for patients with 
Behçet’s disease.
Methods. This methodological study 
enrolled a sample of 125 patients. The 
scale was adapted to Turkish through a 
process including translation, compar-
ison with versions in other languages, 
back translation, and pretesting. Con-
struct validity was evaluated by factor 
analysis. Medication adherence evalu-
ated as poor, moderate and good ac-
cording to the Morisky Medication Ad-
herence Scale (MMAS). BMQ-T scores 
compared along medication adherence 
status groups.
Results. In our study, as in the original 
scale, the factor analysis confirmed that 
the BMQ-T had a four-factor structure 
explaining 54.73% of the total variance. 
The BMQ-T had acceptable internal 
consistency (Cronbach’s alpha coeffi-
cient: Specific Necessity=.812; Specific 
Concerns=.672; General Harm=.677; 
General Overuse=.656), adequate test-
retest reliability (intraclass correlation 
coefficients: Specific Necessity=.715; 
Specific Concerns=.680; General 
Harm=.678; General Overuse=.327). 
Specific Necessity and Specific Con-
cerns scores were significantly different 
between medication adherence status 
groups. 
Conclusion. The psychometric proper-
ties of the BMQ-T were consistent with 
those reported in the original study. 
The BMQ-T was found to be a valid 
and reliable tool for evaluating beliefs 
about medicines in patients with Be-
hçet’s disease. 
Introduction
Behçet’s disease (BD) is a multisystem 
vasculitis with unknown etiology char-
acterized by the heterogeneous nature 
of organ involvement and a fluctuat-
ing disease course (1-3). In the clini-
cal practice, it is not possible to define 
a uniform or standard therapy for BD, 
since the symptoms widely variable. 
The management should be tailored 
to each patient by taking into account 
the existing symptoms, clinical mani-
festations and prognostic factors (3). 
Vascular relapse risk is decreased 
when BD patients are treated with 
immunosuppressives with or without 
anti-coagulation rather than anti-co-
agulation alone (1). There are various 
effective treatment alternatives, while, 
the first and essential step for a suc-
cessful treatment is patients’ adher-
ence to therapy. On the other hand, it 
is estimated that in developed coun-
tries, 40% of patients who suffer from 
chronic diseases do not adhere to treat-
ment recommendations (4). Moreover, 
negative attitudes to medicines appear 
to be prevalent within the community, 
with many patients being suspicious 
of medicine, which further disturbs 
the adherence to treatments. Efforts to 
improve treatment outcomes require a 
better understanding of the particular 
barriers to and facilitators of adherence 
to therapy, and of patient experiences 
of taking treatment (5). Treatment ad-
herence is influenced by many factors, 
among them: i) route of administration, 
ii) psychosocial factors, iii) fear of 
side effects, iv) lack of an immediate 
feeling of benefit, and v) patient atti-
tudes to health and disease and beliefs 
about medicines (6-9). The causes of 
nonadherence can be summarized as 
unintentional and intentional. Inten-
tional nonadherence occurs when the 
patient decides not to take medication 
as advised, and appears to be related 
to patients’ beliefs, and their motiva-
tion to take the prescribed medication, 
whereas unintentional nonadherence 
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is related with patients’ skills or abil-
ity to take that medication (e.g. forget-
fulness or manual dexterity) (10-15). 
Lack of adherence is a critical issue 
in not only BD but also in all chronic 
diseases, and it contributes to a consid-
erable worsening of the disease and an 
increase in healthcare expenditures. In 
this context, increasing the level of the 
patient’s adherence will improve the 
management of a certain disease. For 
this reason, determining the patient at-
titudes and beliefs about medication is 
important, and plays a key role in treat-
ment adherence.
A recent meta-analysis of 94 peer-re-
viewed papers has identified the impor-
tance of patients’ beliefs about medi-
cines as potential determinants of ad-
herence (9). Studies spanning 24 long-
term conditions, involving over 25,000 
patients from 18 countries demonstrate 
that nonadherence is often linked to 
doubts about their personal need for 
the treatment (Necessity beliefs) and to 
concerns about potential adverse con-
sequences of taking it. In these studies 
Necessity beliefs and Concerns were 
assessed using the Beliefs about Medi-
cines Questionnaire (BMQ)©.
The BMQ is composed of two sections: 
the General section (BMQ-General), 
which assesses more general beliefs 
about medicine and includes the Gen-
eral Harm and the General Overuse 
scales; and the Specific section (BMQ-
Specific), which explores beliefs about 
particular medication and comprises 
the Specific Necessity and Specific 
Concerns scales  (10, 16). 
The BMQ has been adapted and used in 
many countries (6, 9, 12, 17), but it has 
not yet been adapted to the Turkish lan-
guage. In addition, as far as we know, 
there is no study assessing the belief 
about the medicine of patients with 
BD. In the present study, we aimed to 
investigate the validity and reliability 
of a Turkish translation of the BMQ in 
patients with BD.
Methods
Study design, sample and setting
The study was planned and applied as 
a methodological study. This study was 
conducted in a single rheumatology 
center. The study was approved by the 
Ethical Review Board of the hospital 
and written informed consent was ob-
tained from each participant.
Patients with BD who were being fol-
lowed-up at the tertiary rheumatology 
outpatient clinic were invited to partic-
ipate to the study. The inclusion crite-
ria for the study as follows: i) fulfilling 
the International Study Group Criteria 
for BD (18); ii) being at age 18 years 
or older; iii) ability to read and write 
Turkish; iv) willingness to participate; 
and v) physically and cognitively able 
to communicate. The exclusion criteria 
consist of: i) having a major psychiatric 
disease diagnosis; ii) having cognitive 
impairment; iii) concurrent terminal 
illness or being clinically unstable. Ul-
timately, a total of 140 patients with 
BD were enrolled in the study. Of 
these, 15 patients did not complete the 
all questionnaires, who were omitted 
from the analysis. Consequently, data 
analyses were subjected to remaining 
125 patients. 
Demographic and disease-related 
variables
Demographic and disease-related vari-
ables including age, gender, duration of 
disease, age of diagnosis, educational 
background, marital and work status, 
and disease properties were recorded. 
Disease activity scores [Behçet’s Dis-
ease Current Activity Form (BDCAF) 
(19) and Behçet’s Syndrome Activity 
Score (BSAS) (20)] were recorded.
Beliefs about medicines questionnaire 
(BMQ) 
BMQ was an established instrument 
for assessing people’s perceptions and 
expectations about medications. It 
contains a general and a specific sec-
tion, with 2 scales each. The scales of 
the BMQ-General are General Harm 
with 4 items and General Overuse 
with 4 items. The BMQ-Specific con-
sists of two five-item scales assessing 
patients’ beliefs about the necessity of 
prescribed medication for controlling 
their disease and their concerns about 
potential adverse consequences of tak-
ing it. Respondents indicate their de-
gree of agreement with each statement 
on a five-point Likert scale, ranging 
from 1=strongly disagree to 5=strongly 
agree. Scores obtained for individual 
items within both scales are summed. 
A mean score for each scale are com-
puted by dividing total scores for that 
scale by the number of items in the 
scale, resulting in a mean score range 
of 1-5 for each scale. Higher scores in-
dicate stronger beliefs in the concepts 
represented by the scale. A necessity–
concerns differential is calculated as 
the difference between the necessity 
and the concerns scales, with a possible 
range of -4 to +4. This differential can 
be thought of as an indicator of how the 
individual judges their personal need 
for the treatment (necessity beliefs) 
relative to their concerns about taking 
it (10, 16).
Morisky Medication Adherence Scale 
(MMAS) 
Medication adherence was assessed us-
ing the Morisky Medication Adherence 
Scale, which is a validated and reli-
able measure, developed by Morisky, 
Green, and Levine (1986). In this scale, 
patients were asked to respond “yes” 
or “no” to the following questions: Do 
you ever forget to take your medicine? 
Are you careless at times about tak-
ing your medicine? Do you sometimes 
stop taking your medicine when you 
are feeling well? When you feel worse 
due to the medicine, do you stop taking 
it? Adherence was assessed on a scale 
of 0 to 4, in which higher scores cor-
respond to lower medication adherence 
and vice versa. Participants were then 
stratified into three groups according 
to their scores: 0 = high medication 
adherence; 1, 2 = medium medication 
adherence; 3, 4 = low medication ad-
herence (21, 22).
Procedure
Written authorization to translate the 
original English version of the BMQ 
into Turkish was obtained from the 
Originator (Prof. Rob Horne UCL 
School of Pharmacy, University Col-
lege London). The English version was 
independently translated into Turkish 
by two bilingual (Turkish and English) 
experts. One of them was a registered 
nurse and the other was a rheumatolo-
gist. A third bilingual expert reviewed 
the two Turkish-translated versions 
3Turkish translation of the beliefs about medicines questionnaire on rheumatology / M. Cinar et al.
and created another version. This ver-
sion was back translated to English 
by two bilingual experts who had not 
read the original version. Thereafter, 
all three versions (original, translated, 
and back-translated) were assessed by 
a panel of three bilingual experts in the 
field (23, 24). Following the transla-
tion/back-translation procedure, the 
final version was checked using a pre-
test technique to verify that they were 
able to understand the instructions, the 
questions, and the different answering 
options (24, 25) and to ensure that the 
language used fits the target popula-
tion of the scale. Two weeks later, the 
Turkish version of the BMQ was ad-
ministered again to 41 patients. These 
results were used to evaluate test-retest 
reliability.
Data analysis
All statistical analyses were conducted 
using the SPSS for Windows version 
21.0 statistical software (IBM Inc, 
USA). Descriptive statistics (means, 
standard deviations [SDs], frequency 
distributions, percentages) were com-
puted. 
Internal consistency of BMQ-Turkish 
Translation (BMQ-T) was evaluated 
by Cronbach’s alpha coefficient from 
baseline results of the patients. The 
BMQ-T questionnaire was applied 
two times at a two-week interval by 
the same researcher. Intraclass correla-
tion coefficient (ICC) was calculated 
to assess test–retest reliability, and the 
paired samples t test was performed to 
represent there is no differences be-
tween first and second BMQ-T points.
The measure validity of the BMQ was 
assessed by computing the correla-
tion coefficient between the BMQ-T 
scores and the MMAS. Patients were 
grouped in three categories according 
to MMAS scores. Mean BMQ scores 
of these groups were compared using 
ANOVA, with Tukey HSD as the post 
hoc test. Construct validity was evalu-
ated by exploratory factor analysis. 
Principle component analysis (PCA) 
was conducted with varimax rotation. 
The Kaiser-Meyer-Olkin test was per-
formed to evaluate sample adequacy. 
The number of components was deter-
mined according to eigenvalue. In this 
study, p values less than .05 were con-
sidered to be statistically significant.
Results
Participant characteristics
A total of 125 patients had completed 
the study protocol. The mean age of 
these patients was 31.42±8.11 years. 
Mean disease duration was 9.34±5.76 
years. The study population was male 
predominant (91.2%) and about half 
of the patients were single (53.6%). 
Twenty-nine (23.2%) of the patients 
were primary school graduate, 41 
(32.8%) were high school graduate, and 
55 (44.0%) were university and higher 
graduate. All of the patients had cur-
rent or a history of oral aphthae. Other 
skin lesions, such as papulopustular le-
sions, genital ulcers, and erythema no-
dosum were present in 96.0%, 84.8%, 
and 52.0% of the patients, respectively. 
The most frequent organ involvement 
was ocular disease with a frequency 
of 41.6%. Other involvements such as 
joint, vascular, central nervous system, 
and gastrointestinal diseases were seen 
in 29.6%, 17.6%, 5.6%, and 0.8% of 
patients, respectively. The pathergy 
test was positive in 46.4% of the pa-
tients. The HLA-B51 test was positive 
in 30 of 43 patients who were tested. 
The clinical features of the study group 
are presented in Table I. 
Among the current treatment agents, 
colchicine was the most commonly 
used one (76.8%). Sixty-seven pa-
tients were using at least one immune 
suppressive drug (azathioprine, cy-
closporine A and cyclophosphamide). 
Other medications such as corticoster-
oids and anticoagulant agents were be-
ing used in 20 and 9 patients, respec-
tively. Other medicines including inf-
liximab, sulfasalazine, methotrexate, 
and nonsteroidal anti-inflammatory 
drugs (NSAIDs) were being used by a 
minority of the patients (each, <5%). 
Table I. Clinical features of patients (n = 125).
Characteristics  n (%)
Oral aphthae 125 (100.0)
Papulopustular skin lesion (acneiform, ostiofolliculitis, etc.) 120 (96.0)
Genital ulcer 106 (84.8)
Erythema nodosum 65 (52.0)
Ocular involvement 52 (41.6)
Joint (arthritis) involvement 37 (29.6)
Vascular involvement 22 (17.6)
Central nervous system involvement 7 (5.6)
Gastrointestinal system involvement 1 (0.8)
Pathergy positivity 58 (46.4)
HLA-B51, positive, (n=43) 30 (69.8)
BDCAF (mean ± SD), (range 0-12) 4.79 ± 2.05
BSAS (mean ± SD), (range 0-100) 45.22 ± 23.56
Used drugs* 
 Colchicine  96 (76.8)
 Azathioprine  56 (44.8)
 Corticosteroids  20 (16.0)
 Anticoagulant  9 (7.2)
 Cyclosporine A 6 (4.8)
 Infliximab 5 (4.0)
 Cyclophosphamide 5 (4.0)
 NSAIDs 4 (3.2)
 Methotrexate 3 (2.4)
 Sulfasalazine 2 (1.6)
Experiencing drug related adverse events 40 (32.0)
Gastrointestinal (abdominal pain, distension, nausea, vomiting, diarrhea, 20 (16.0) 
 loss of appetite) 
Elevation in liver enzymes  10 (8.0)
Skin (pruritis, rash, ecchymosis, acne, alopecia) 6 (4.8)
Constitutional (weakness, fatigue, headache, dizziness) 2 (1.6)
Allergic reactions 1 (0.8)
Diminished libido 1 (0.8)
Data represented either as the mean ± SD or as the frequency; *More than 1 agent might have been used 
in the same patient; NSAIDs: nonsteroidal anti-inflammatory drugs; BDCAF: Behçet’s disease current 
activity form; BSAS: Behçet’s syndrome activity score; SD: standard deviation.
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Drug-related adverse events were ex-
perienced by 32.0% of the patients. 
Among those, gastrointestinal and he-
patic side effects were the leading ones 
(16.0% and 8.0%, respectively) (Table 
I).
According to the MMAS scores, 32 
(25.6%) patients had high, 69 (55.2% 
patients had moderate, and 24 (19.2%) 
patients had low medication adherence. 
Total MMAS score were 1.43±1.16 
(min-max, 0-4).
Reliability
The BMQ-Specific Necessity Cron-
bach’s alpha coefficient was .812, 
BMQ-T-Specific Concern Cronbach’s 
alpha coefficient was .672, BMQ-T-
General Harm Cronbach’s alpha co-
efficient was .677, BMQ-T-General 
Overuse Cronbach’s alpha coefficient 
was .656. The total BMQ-T-Specific 
Cronbach’s alpha coefficient was .774, 
the total BMQ-T-General Cronbach’s 
alpha coefficient was .730. The paired 
samples t test demonstrated that there 
was no difference between test and re-
test scores of the whole scales of BMQ-
T (p>.05). In the correlation analysis 
performed for the test–retest reliability, 
an adequate statistically significant and 
positive correlation was observed be-
tween the first test and the retest scores 
(p<.05) (Table II).
Validity
The Morisky scale classifies patient 
adherence as high, medium, and low. 
In our comparative analysis, a sta-
tistically significant difference was 
found between these groups with 
respect to the total BMQ-T scores 
(except for BMQ-T-General Harm). 
We performed a post hoc analysis to 
identify the cause of this difference; 
we found that the BMQ-T-Specific 
Necessity mean score of patients with 
high Morisky drug adherence was 
higher from those in the medium and 
low drug adherence groups (p=.022), 
BMQ-T-Specific Concerns mean 
score of patients with high Morisky 
drug adherence was lower from those 
in the medium and low drug adher-
ence groups (p=.006) and BMQ-T-
General Overuse mean score of pa-
tients with medium Morisky drug ad-
herence was lower from those in the 
low drug adherence groups (p=.024) 
(Table III). There was no correlation 
between BMQ-T-General Harm score 
and both the total MMAS and classi-
fied MMAS scores.
Construct validity was evaluated by 
factor analysis. The original scale con-
sisted of four components. As a result 
of our analysis, that the items separated 
into four components in Principle Com-
ponent Analysis. The total explained 
variance was 54.73%, and the lowest 
item load was .46. The Kaiser-Meyer-
Olkin measure of sample adequacy was 
found to be .71 (Table IV).
At the result of the PCA, item 5 was 
classified more closely with General 
Overuse questions, rather than its 
components. But the factor load with 
Specific Concerns questions was cal-
culated as .318. The factor structure 
we have achieved was considered to 
be highly consistent with the original 
structure of the scale, and it had an ap-
propriate and close scoring and classi-
fication to the original. 
We calculated a Necessity Concerns 
Differential (NCD) by subtracting 
mean Concerns Scale scores from Ne-
cessity scale scores (scale scores range 
from -4 to +4). The mean Necessity-
Concerns differential was found to be 
0.47±0.91 (range -1.8 to 3).
Discussion
This was the first study to assess the 
reliability and validity of the Turkish 
translation of the BMQ. The prevalence 
rate of BD was between 20-421 among 
100,000 in adolescent/adult popula-
tion in Turkey (26-28). BD, for many 
patients, is a disease that impairs the 
quality of life by frequently relapsing 
mucocutaneous manifestations. How-
ever, there are also many who carry an 
increased risk of significant morbidity 
or even mortality as a consequence of 
vital organ involvement. Many factors, 
including patient’s sex, age of disease 
onset, the disease duration and patient 
attitudes and beliefs about medica-
tion need to be considered when plan-
ning treatment for a patient with BD. 
In this context, we decided to conduct 
the study in these patients. This study 
results supported the validity and reli-
ability of the BMQ-T.
The BMQ-T showed adequate reliabil-
ity for clinical application. Internal con-
sistency of the total BMQ-T (Specific 
and General) was supported by Cron-
bach’s alpha coefficients (.774 and .730 
respectively). In the correlation analysis 
performed for the test–retest reliability, 
an adequate statistically significant and 
positive correlation was observed be-
tween the first test and the retest scores 
(Table II). The validity of the BMQ-
Table II. Comparison and correlations of the BMQ-T test-retest scores.
Application Test Retest (n=41) t p* r p** 
 (n=125) 
BMQ-T-Specific Necessity 3.69 ± 0.80 3.61 ± 0.91 1.301 .201 .715 < .001
BMQ-T-Specific Concerns 3.22 ± 0.78 3.23 ± 0.73 1.636 .110 .680 < .001
BMQ-T-General Harm 2.37 ± 0.71 2.38 ± 0.82 .755 .455 .678 < .001
BMQ-T-General Overuse 2.68 ± 0.75 2.67 ± 0.75 -.391 .698 .327 .017
Note: BMQ-T: Turkish version of the Beliefs About Medicines Questionnaire; *Paired samples t test; 
**Intraclass correlation coefficient (ICC).
Table III. Comparison of the BMQ-T with the Morisky scale sub-groups.
 Morisky drug adherence F* p 
 High Medium Low  
BMQ-T-Specific Necessity 4.00 ± 0.63 3.63 ± 0.86 3.43 ± 0.75 3.95 .022¥
BMQ-T-Specific Concerns 2.91 ± 0.81 3.25 ± 0.76 3.58 ± 0.67 5.335 .006#
BMQ-T-General Overuse 2.59 ± 0.70 2.59 ± 0.73 3.05 ± 0.77 3.86 .024≠
BMQ-T-General Harm 2.31 ± 0.81  2.36 ± 0.67  2.50 ± 0.71 .545 .581
Note: *Oneway ANOVA; ¥Statistically significant between high and low scores; #Statistically signifi-
cant between high and low scores; ≠Statistically significant between medium and low scores.
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Specific scales was assessed in different 
languages including Portugal, English, 
German and Italian. In the Portuguese, 
German, and Italian versions of the 
BMQ-Specific, the results had provided 
good support for confirming the reliabil-
ity. In our study, the Cronbach’s alphas 
for the Necessity and Concerns scales 
(0.812 and 0.672 respectively) were in 
agreement with the values of Portuguese 
(0.757 and 0.665, respectively), Italian 
(0.78 and 0.72, respectively) and Eng-
lish versions (ranged from 0.55 to 0.86 
and from 0.63 to 0.80 for the Necessity 
and Concerns scales, respectively) (12, 
16, 29). However, the German version 
values (0.83 for both scales) were high-
er than the Cronbach’s alphas attained 
for the Portuguese, Italian, English and 
our study results (30). In our study, the 
BMQ-T-General results also provide 
good support for confirming the reliabil-
ity. The Cronbach’s alphas for the Over-
use and Harm scales (.656 and .677, 
respectively) were in agreement with 
the values reported for the original Eng-
lish version, in which Cronbach’s alpha 
ranged from .60 to .80 and from .47 to 
.83 for the Overuse and Harm scales, 
respectively (16). These previous stud-
ies validating the BMQ-T indicate this 
scale has adequate reliability, and simi-
lar results were found in our study.
In our study, the construct validity of 
the scale was evaluated by factor anal-
ysis. The Kaiser-Meyer-Olkin meas-
ure of sample adequacy was found to 
be .71 and considered adequate. The 
total explained variance was 54.73%, 
and the lowest item load was .46. The 
factor structure we have achieved was 
considered to be highly consistent with 
the original structure of the scale, and 
it had an appropriate and close scoring 
and classification to the original (Table 
IV). Finally, the construct validity of 
our translated questionnaire was evalu-
ated as satisfactory. 
The MMAS is commonly used in 
medication adherence studies (13). 
Morisky et al. (21) developed a brief, 
easily understood, and valid scale to 
be administered to patients in the clini-
cal setting. In the present study, the 
medication adherence was evaluated 
with MMAS. According to the MMAS 
scores, medium and high levels of 
medication adherence were observed 
in the majority of the patients. While 
reported average medication adherence 
scores range between 43-78% in clini-
cal trials, it is estimated that in devel-
oped countries (31), 40% of patients 
who suffer from chronic diseases do 
not adhere to treatment recommenda-
tions (4). In the present study, medica-
tion adherence in BD patients seems to 
be better as compared to the historical 
data in other patient populations, while 
to our knowledge no data existed in BD 
patients. While we categorized our data 
into three groups according to MMAS 
scores, there was a statistically sig-
nificant difference among these groups 
for BMQ-T scores except for BMQ-T-
General Harm (Table III). It has been 
reported that General Harm and Gen-
eral Overuse beliefs were associated 
with Specific Concerns about medica-
tion prescribed for them by their doc-
tors (7, 16). Our findings are consistent 
with theoretical predictions that non-
adherence is likely to be more closely 
with specific beliefs than with general 
beliefs (32).
Several validation studies focused on 
different languages for this scale have 
been conducted on different diseases. 
It is reported that the two sections of 
the BMQ can be used in combination 
or separately. Salgado et al. (12) have 
done just Portuguese validation of the 
BMQ-Specific sections. De las Cue-
vas et al. (17) on psychiatric patients, 
Perpiñá Tordera et al. (6) on Asthma 
patients also have made on the valid-
ity of the scale. They found compatible 
with the original version of the results. 
In our study, similar to the original ver-
sion and previous studies, both gen-
eral and specific parts of the scale was 
found to be validated.
Patient’s with stronger beliefs in the 
necessity of their medication (high 
scores on the BMQ–Necessity scale) 
were significantly more adherent. 
Those with stronger concerns (high 
scores on the BMQ-Concerns scale) 
were significantly less adherent (10). 
In our study, we also found similar re-
sults. We have found that, the patients 
with higher drug adherence had also 
higher Specific Necessity scores, those 
Table IV. Results of the principal components analysis with varimax rotation of the BMQ-
T (n = 125).
  
 New Component
 Original  1 2 3 4
 Component (SN) (GO) (SC) (GH)
Without this medicine I would be very ill SN (item 4) .814   
My health, at present, depends on this medicine SN (item 1) .761   
My life would be impossible without this medicine SN (item 3) .752   
My health in the future will depend on this medicine SN (item 7) .682   
This medicine protects me from becoming worse SN (item 10) .667   
If doctors had more time with patients they would GO (item 18)  .672 
   prescribe fewer medicines   
People who take medicines should stop their GO (item 12)  .633 
   treatment for a while every now and again   
Doctors place too much trust on medicines GO (item 17)  .619  
I sometimes worry about long-term effects of this SC (item 5)  .549 
   medicine   
Doctors use too many medicines GO (item 11)  .538  
Having to take this medicine worries me SC (item 2)   .608 
This medicine is a mystery to me SC (item 6)   .584 
This medicine disrupts my life SC (item 8)   .544 
I sometimes worry about becoming too dependent SC (item 9)   .539 
   on this medicine  
All medicines are poisons GH (item 16)    .788
Medicines do more harm than good GH (item 15)    .737
Natural remedies are safer than medicines GH (item 14)    .533
Most medicines are addictive GH (item 13)    .461
Eigenvalue  3.75 3.34 1.40 1.37
% of variance  20.83 18.53 7.77 7.59
Cumulative % of variance     54.73
SN: Specific Necessity; SC: Specific Concerns; GH: General Harm; GO: General Overuse.
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with lower drug adherence, had higher 
Specific Concerns scores.  
The Turkish translation of the BMQ 
exhibited good to excellent internal 
consistency and its structure and con-
tent provided a perfect fit to those of 
the original questionnaire. Our findings 
underscore the usefulness of the BMQ-
T for assessing beliefs that patients 
with BD hold about the medicines 
they use. Therefore, further studies are 
needed to investigate the reliability and 
validity of this scale in different clini-
cal settings and different populations.
Conclusion 
The Turkish version of the BMQ is a 
simple, and inexpensive to administer, 
and a convenient measurement of pa-
tients’ attitudes and beliefs about their 
medication in patients with BD. In ad-
dition, it was demonstrated to have ac-
ceptable reliability and validity. 
Limitation 
This study depends on a patient-re-
ported questionnaire; therefore, this 
is a potential limitation of the present 
study. Natural drawbacks of this type 
of study, such as recall bias and false 
declarations of patients, might cause 
potential risk of bias.
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